These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23106384)

  • 1. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.
    Kerk N; Drabik A; Luger TA; Schneider SW; Goerge T
    Br J Dermatol; 2013 Apr; 168(4):898-9. PubMed ID: 23106384
    [No Abstract]   [Full Text] [Related]  

  • 2. Response of livedoid vasculopathy to rivaroxaban.
    Winchester DS; Drage LA; Davis MD
    Br J Dermatol; 2015 Apr; 172(4):1148-50. PubMed ID: 25255997
    [No Abstract]   [Full Text] [Related]  

  • 3. Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction.
    Kerk N; Goerge T
    J Dtsch Dermatol Ges; 2013 May; 11(5):407-10. PubMed ID: 23437985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Livedoid vasculopathy. Pathogenesis, diagnosis and treatment of cutaneous infarction].
    Goerge T
    Hautarzt; 2011 Aug; 62(8):627-34; quiz 635. PubMed ID: 21786003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.
    Furukawa F; Mizawa M; Makino T; Shimizu T
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28739563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists.
    Jiménez-Gallo D; Villegas-Romero I; Rodríguez-Mateos ME; Linares-Barrios M
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):278-281. PubMed ID: 29074145
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban.
    Drerup C; Goerge T
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e532. PubMed ID: 28609556
    [No Abstract]   [Full Text] [Related]  

  • 8. Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment.
    Lee JS; Cho S
    J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):e176-e178. PubMed ID: 31793049
    [No Abstract]   [Full Text] [Related]  

  • 9. New oral anticoagulants show promise.
    Hampton T
    JAMA; 2006 Feb; 295(7):743-4. PubMed ID: 16478891
    [No Abstract]   [Full Text] [Related]  

  • 10. Lysis of thrombus located in the left atrial appendage. Is it the right time for a Xa factor inhibitor?
    Baran J; Zaborska B; Sikora-Frąc M; Stec S; Kułakowski P
    Kardiol Pol; 2013; 71(11):1210. PubMed ID: 24297727
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to "Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban".
    Turpie AG
    J Clin Pharmacol; 2011 Jul; 51(7):1122-3. PubMed ID: 21666147
    [No Abstract]   [Full Text] [Related]  

  • 12. Livedoid vasculopathy secondary to high levels of lipoprotein(a).
    Vasconcelos R; Criado PR; Belda W
    Br J Dermatol; 2011 May; 164(5):1111-3. PubMed ID: 21219292
    [No Abstract]   [Full Text] [Related]  

  • 13. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new era in secondary prevention after acute coronary syndrome.
    Roe MT; Ohman EM
    N Engl J Med; 2012 Jan; 366(1):85-7. PubMed ID: 22077849
    [No Abstract]   [Full Text] [Related]  

  • 15. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
    Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
    Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
    Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1784-1791. PubMed ID: 31009111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban for thromboprophylaxis.
    ten Cate H; Hamulyak K
    N Engl J Med; 2008 Nov; 359(20):2174-5; author reply 2176. PubMed ID: 19009676
    [No Abstract]   [Full Text] [Related]  

  • 18. Rivaroxaban for thromboprophylaxis.
    Schuman EP
    N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19005203
    [No Abstract]   [Full Text] [Related]  

  • 19. Livedo vasculopathy associated with IgM anti-phosphatidylserine-prothrombin complex antibody.
    Tabata N; Oonami K; Ishibashi M; Yamazaki M
    Acta Derm Venereol; 2010 May; 90(3):313-4. PubMed ID: 20526560
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid remission of severe pain from livedoid vasculopathy by apixaban.
    Yamaguchi Y; Nakazato S; Izumi K; Ieko M; Nomura T; Shimizu H
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e45-e46. PubMed ID: 27166520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.